(CBAT) CBAK Energy Technology - Ratings and Ratios

CBAK Energy Technology Inc, a China-based company listed on NASDAQ under the ticker symbol CBAT, operates in the electrical components and equipment sub-industry. The company is a leading manufacturer and distributor of lithium and sodium batteries, catering to a diverse range of applications including electric vehicles, electric bicycles, and energy storage systems. With a presence in Mainland China, Europe, and internationally, CBAK Energy Technology has established itself as a significant player in the global battery market.

The companys product portfolio includes standard and customized lithium and sodium batteries, as well as nickel-cobalt-manganese precursor and cathode materials. These products are used in various industries, including automotive, consumer electronics, and renewable energy. CBAK Energy Technologys business is divided into two segments: CBAK and Hitrans, allowing the company to effectively manage its operations and capitalize on emerging opportunities.

Analyzing the , we observe that the stocks last price is $0.87, with a 20-day simple moving average (SMA) of $0.81 and a 50-day SMA of $0.79, indicating a short-term uptrend. However, the 200-day SMA stands at $0.93, suggesting a longer-term downtrend. The average true range (ATR) is $0.06, representing a volatility of 6.53%. Considering the , the companys market capitalization is approximately $84.09 million, with a price-to-earnings (P/E) ratio of 7.19 and a forward P/E of 22.62. The return on equity (RoE) is -2.04%, indicating a negative return on shareholder equity.

Combining the insights from and , we can forecast that CBAK Energy Technologys stock price may experience a short-term consolidation around the $0.80-$0.90 range, given the current SMA20 and SMA50 levels. However, the stocks long-term trajectory is uncertain due to the negative RoE and relatively low market capitalization. If the company can improve its profitability and expand its market share, the stock price may potentially break above the 200-day SMA of $0.93, targeting the 52-week high of $1.89. Conversely, failure to address the negative RoE and other fundamental concerns may lead to further declines, potentially testing the 52-week low of $0.64.